C. Vens

发表

Irradiation-induced damage and the DNA damage response

B. Wouters, M. Koritzinsky, C. Vens, 2018, Basic Clinical Radiobiology.

Strategies to improve radiotherapy with targeted drugs

Fiona A. Stewart, Conchita Vens, F. Stewart, 2011, Nature Reviews Cancer.

Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association

Michiel W M van den Brekel, Conchita Vens, Lodewyk F A Wessels, 2018, PloS one.

Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models.

J. Sonke, R. Coppes, M. Verheij, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Robust BRCA1‐like classification of copy number profiles of samples repeated across different datasets and platforms

S. Chin, A. Tutt, C. Caldas, 2015, Molecular oncology.

Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy.

C. R. Leemans, P. Essers, M. Verheij, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2)

E. van de Steeg, A. Schinkel, E. Wagenaar, 2008, Drug Metabolism and Disposition.

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

J. Armenia, A. Lau, M. O’Connor, 2021, Molecular Cancer Therapeutics.

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

M. O’Connor, J. Jonkers, M. Verheij, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.

S. Zerp, M. Verheij, B. van Triest, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology

P. Lambin, L. Dubois, A. Yaromina, 2022, Cancers.

Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.

F. Hoebers, C. Terhaard, M. Heymans, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

UvA-DARE (Digital Academic Repository) Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma

Marcel, Hageman, T. Severson, 2018 .

Quantitative, real-time analysis of base excision repair activity in cell lysates utilizing lesion-specific molecular beacons.

R. Sobol, C. Vens, D. Svilar, 2012, Journal of visualized experiments : JoVE.

The role of DNA polymerase beta in determining sensitivity to ionizing radiation in human tumor cells

Conchita Vens, Els Dahmen-Mooren, Manon Verwijs-Janssen, 2002, Nucleic Acids Res..

Rapid Fluorescence Ratio Assay for Detecting Changes in Radiosensitivity

A. Begg, I. Hofland, C. Vens, 2002, Radiation research.

Involvement of DNA Polymerase Beta in Repair of Ionizing Radiation Damage as Measured by In Vitro Plasmid Assays

A. Begg, I. Hofland, C. Vens, 2007, Radiation research.

Genetic manipulation of radiosensitivity.

A. Begg, C. Vens, 2001, International journal of radiation oncology, biology, physics.

Targeting DNA Repair Pathways for Cancer Therapy

R. Sobol, C. Vens, 2013 .

Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}.

Lenie J. van den Broek, A. Begg, C. Vens, 2010, Cancer research.

Targeting base excision repair as a sensitization strategy in radiotherapy.

A. Begg, C. Vens, 2010, Seminars in radiation oncology.

Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta.

A. Begg, E. Dikomey, C. Vens, 2009, DNA repair.

Role for DNA polymerase beta in response to ionizing radiation.

A. Begg, P. Cramers, C. Vens, 2007, DNA repair.

Radiosensitization by a dominant negative to DNA polymerase β is DNA polymerase β-independent and XRCC1-dependent

A. Begg, C. Vens, S. Neijenhuis, 2005 .

Radiosensitization by a dominant negative to DNA polymerase beta is DNA polymerase beta-independent and XRCC1-dependent.

A. Begg, C. Vens, S. Neijenhuis, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer.

L. Wessels, L. Wessels, M. Verheij, 2018, Oral oncology.

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy

Michiel W M van den Brekel, Conchita Vens, Lodewyk F A Wessels, 2019, Cancers.

Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma

Lodewyk F.A. Wessels, Conchita Vens, Arno Velds, 2018, Oncotarget.

Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity

H. Ovaa, J. Neefjes, P. Halonen, 2017, Oncotarget.

Cellular Radiosensitivity of Soft Tissue Sarcoma

F. van Coevorden, R. Haas, W. V. van Houdt, 2021, Radiation Research.

Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells

M. Serresi, P. V. D. van den Berk, E. Citterio, 2014, The Journal of experimental medicine.

Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective.

M. Verheij, B. van Triest, C. Vens, 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β

Nathan A. Yates, Conchita Vens, Robert W. Sobol, 2014, Nature Communications.

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

J. Schellens, M. Verheij, D. Pluim, 2020, Clinical Cancer Research.

DNA Repair Molecular Beacon assay: a platform for real-time functional analysis of cellular DNA repair capacity

S. McClellan, R. Sobol, Jianfeng Li, 2018, Oncotarget.

Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity

H. Ovaa, J. Neefjes, P. Halonen, 2017, Oncotarget.

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

J. Schellens, M. Verheij, J. Schellens, 2019, BMC Cancer.

Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation

P. Lambin, H. Bartelink, F. Hoebers, 2020, Frontiers in Oncology.

Drug sensitivity prediction models reveal a link between DNA repair defects and poor prognosis in HNSCC.

H. Bartelink, C. R. Leemans, P. Essers, 2019, Cancer research.

Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status.

A. Begg, H. Janssen, C. Vens, 2006, International journal of radiation oncology, biology, physics.

Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy

I. Huijbers, P. Essers, S. Rottenberg, 2022, Cancer research communications.

Ovarian cancer‐derived copy number alterations signatures are prognostic in chemoradiotherapy‐treated head and neck squamous cell carcinoma

H. Bartelink, C. R. Leemans, P. Essers, 2020, International journal of cancer.

Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients

F. Hoebers, C. Leemans, M. Verheij, 2019, Cancers.

Ionizing Radiation Sensitivity of DNA Polymerase Lambda-Deficient Cells

B. Bertocci, A. Begg, C. Vens, 2007, Radiation research.

New challenge of developing combined radio-drug therapy.

V. Grégoire, P. Maingon, E. Shash, 2014, Chinese clinical oncology.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

Conchita Vens, Heike Peulen, J. Schellens, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent

M. O’Connor, J. Jonkers, M. Verheij, 2015 .

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

J. Schellens, M. Verheij, B. van Triest, 2019, BMC Cancer.

Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy

Frank Hoebers, Philippe Lambin, Kathrin Scheckenbach, 2020, PloS one.

Cell cycle phase dependent role of DNA polymerase beta in DNA repair and survival after ionizing radiation.

A. Begg, C. Vens, C. Vermeulen, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association

L. Wessels, M. Verheij, C. Vens, 2018, PloS one.

Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland.

Jeroen de Jong, Conchita Vens, Ghazaleh Ghobadi, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.